Polypharmacy or ECT? Side effects profile comparison in patients with resistant schizophrenia
Abstract
The data about treatment resistant paranoid schizophrenia patients getting electroconvulsive therapy (ECT) together with antipsychotic agents and about the patients receiving combined antipsychotics treatment only is observed in the article. The side effects spectrum is analyzed with the help of UKU standardized scale. Patients getting combined ECT and antipsychotics treatment have less intensity and greater reduction of some specific side effects groups during the course of antipsychotic treatment.
About the Author
D. S. Zubov
ФГБУ «Национальный медицинский исследовательский центр психиатрии и неврологии имени В.М. Бехтерева» Минздрава России
Russian Federation
Russian Federation
References
1. McGrath J., Saha S., Chant D. et al. Schizophrenia: a concise overview of incidence, prevalence, and mortality. // Epidemiologic Reviews. - 2008. - Vol. 30. - P. 67-76.
2. Bayley R. First person account: schizophrenia. // Schizophrenia Bulletin. - 1996. - Vol. 22 (4). - P. 727-729.
3. Altamura C., Fagiolini A., Galderisi S. et al. Schizophrenia today: epidemiology, diagnosis, course and models of care // Journal of Psychopathology. - 2014. - Vol. 20. - P. 223-243.
4. Caccia S., Invernizzi R. W., Nobili A. et al. A new generation of antipsychotics: pharmacology and clinical utility of cariprazine in schizophrenia. // Ther Clin Risk Manag. - 2013. - Vol. 9. - P. 319-328.
5. Abbott C. C., Jaramillo A., Wilcox C. E. et al. Antipsychotic Drug Effects in Schizophrenia: A Review of Longitudinal fMRI Investigations and Neural Interpretations. // Curr Med Chem. - 2013. - Vol. 20 (3). - P. 428-437.
6. Gallini A., Huskamp H.A., Donohue J.M. Technology diffusion in the antipsychotic market: a comparison of France and the USA between 1998 and 2008. // Psychiatric Services. - 2013. - Vol. 64 (7). - P. 680-687.
7. Hirsch L., Yang J., Bresee L. et al. Second-Generation Antipsychotics and Metabolic Side Effects: A Systematic Review of Population-Based Studies. // Drug Safety. - 2017.
8. Seong S. Shim. Treatment-Resistant Schizophrenia. // Psychiatric times. - 2009.
9. Kane J., Honigfeld G., Singer J. et al. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorproma-zine. // Archives of General Psychiatry. - 1988. - Vol. 45 (9). - P. 789-796.
10. Молосов С.Н. Резистентность к психофармакотерапии и методы её преодоления. // Психиатрия и психофармакотерапия. - 2002. - Том 4, № 4.
11. Nasrallah H.A. Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. // Molecular Psychiatry. - 2008. - Vol. 13 (1). - P. 27-35.
12. Englisch S., Zink M. Treatment-resistant Schizophrenia: Evidence-based Strategies. // Mens Sana Monographs. - 2012. - Vol. 10 (1). - P. 20-32.
13. Combination and High-Dose Atypical Antipsychotic Therapy in Patients with Schizophrenia: Systematic Review. // CADTH Technol Overv. - 2012. - Vol. 2 (3).
14. Mossaheb N., Kaufmann R.M. Role of aripiprazole in treatment-resistant schizophrenia. // Neuropsychiatr Dis Treat. - 2012. - Vol. 8. - P. 235-244.
15. Ortiz-Orendain J., Castiello-de Obeso S., Colunga-Lozano L.E. et al. Antipsychotic combinations for schizophrenia. // The Cochrane Database of Systematic Reviews. - 2017.
16. Greenhalgh J., Knight C., Hind D. et al. Clinical and cost-effectiveness of electroconvulsive therapy for depressive illness, schizophrenia, catatonia and mania: systematic reviews and economic modelling studies. - 2005.
17. Dabrowski M., Parnowski M. Clinical analysis of safety and effectiveness of electroconvulsive therapy. // Psychiatria Polska. - 2012. - Vol. 46 (3). - P. 345-360.
18. Watts B.V., Groft A., Bagian J.P. et al. An examination of mortality and other adverse events related to electroconvulsive therapy using a national adverse event report system. // The Journal of ECT. - 2011. - Vol. 27 (2). - P. 105-108.
19. Andrade C., Arumugham S.S., Thirthalli J. Adverse Effects of Electroconvulsive Therapy. // The Psychiatric Clinics of North America. - 2016. - Vol. 39 (3). - P. 513-530.
20. Payne N.A., Prudic J. Electroconvulsive Therapy Part I: A Perspective on the Evolution and Current Practice of ECT. // J Psychiatr Pract. - 2009. - Vol. 15 (5). - P. 346-368.
21. McFarquhar T.F., Thompson J. Knowledge and attitudes regarding electroconvulsive therapy among medical students and the general public. // The Journal of ECT. - 2008. - Vol. 24 (4). - P. 244-253.
22. Голенков А. В. Отношение разных групп населения к электросудорожной терапии. // Медицинская психология в России. - 2011. - № 5 (10).
23. American Psychiatric Association Practice and Guidilenes for the Psychiatric Evaluation for Adults. - 2004.
24. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. // Schizophrenia Bulletin. - 1987. - 13 (2). - 261-76.
25. Lingjœrde O., Ahlfors U.G., Bech P., et al. UKU Side Effects Rating Scale // Acta Psychatr Scand. - 1987. - 76; Suppl. 334.
Review
For citations:
Zubov D.S. Polypharmacy or ECT? Side effects profile comparison in patients with resistant schizophrenia. Medical alphabet. 2017;2(21):52-57. (In Russ.)
Views:
244
Email this article 